Research » Renal Transplant
The incidence of acute kidney injury and chronic renal disease is increasing and renal transplantation provides clear benefits for patients with end stage kidney disease. These include better quality of life, improved survival and, with an average cost of dialysis of £30,800 per patient per year, savings of >£500 million for patients with currently functioning transplants, compared with dialysis.
In 2011, 2,782 renal transplants were performed in the UK. However, early complications can significantly impact clinical and economic outcomes, such as delayed graft function (DGF) which affects ~25% of patients and acute rejection which affects 10-25% of patients. Both DGF and AR increase the risk of graft failure. Serum creatinine is currently used in the diagnosis of complications although its sensitivity is poor, with subsequent renal biopsy which carries significant associated morbidity.
We are interested in finding biomarkers which could:
- complement/replace creatinine as indicators of renal function;
- provide diagnostic and prognostic information about complications of renal transplantation to allow tailoring of therapies and follow-up.
Such markers may also provide knowledge about underlying mechanisms and indicate further possible pathways for therapeutic targeting.
Our NIHR Biomarker Programme is also integrated with this research with one workstream involving collecting fluid and tissue samples from 300 patients undergoing renal transplantation at up to 10 centres round the UK, collecting urine and serum/plasma samples longitudinally and extensive clinical follow-up data. These will be used for validation of promising markers from our own studies and those of others.